Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity (2009 - 2026)

Regeneron Pharmaceuticals has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $41.7 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 9.19% year-over-year to $41.7 billion in Q2 2026; TTM through Jun 2026 was $163.3 billion, a 8.19% increase from a year earlier, with the FY2025 full-year figure at $40.6 billion, up 7.41% from the prior year.
• Liabilities and Shareholders Equity was $41.7 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $40.9 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $41.7 billion in Q2 2026, with the low at $26.3 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $34.5 billion, with a median of $35.2 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 48.26% in 2022, then increased 5.91% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $29.2 billion in 2022, then rose by 13.23% to $33.1 billion in 2023, then gained by 14.15% to $37.8 billion in 2024, then grew by 7.41% to $40.6 billion in 2025, then climbed by 2.89% to $41.7 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $41.7 billion (Q2 2026), $40.9 billion (Q1 2026), and $40.6 billion (Q4 2025), per Business Quant data.